Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
sponsorship: Support for the "Glycemic Outcomes Beyond A1C: Standardization and Implementation" meeting and development of this article was provided by The diaTribe Foundation. Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Becton Dickinson, Eli Lilly, Merck, Novo Nordisk, Sanofi, and The Apple Pickers Foundation provided funding to The diaTribe Foundation to support the consensus meeting. The diaTribe Foundation contracted with James S. Hirsch and C.G.P. for editorial support. S. A. has served on advisory boards for Novo Nordisk, Medtronic, and Roche. R.B.'s nonprofit employer has received consultant payments, research funds, or research supplies on his behalf from Abbott Diabetes Care, Animas, Ascenia, Bigfoot Biomedical, Dexcom, Insulet, Eli Lilly, Roche, and Tandem, with no personal compensation to R.B. R.M.B. declared research support, acted as a consultant, or has been on a scientific advisory board for Abbott Diabetes Care, Becton Dickinson, Dexcom, Eli Lilly, Glooko, Helmsley Charitable Trust, Hygieia, Johnson & Johnson, Medtronic, Merck, Novo Nordisk, Roche, and Sanofi. R.M.B.'s nonprofit employer contracts for his services and no personal income goes to R.M.B. He has inherited Merck stock. He is a volunteer for ADA and JDRF and has worked on the development and implementation of the AGP. Z.B. is a consultant/adviser for Sanofi, AstraZeneca, Janssen, Merck, Intarcia, and Novartis; a speaker for Amgen, Merck, AstraZeneca, and Janssen; and a stockholder in Allergan, Zimmer Biomet, and Novartis. A.B., K.L.C., I.C., and E.F. report disclosures for The diaTribe Foundation, which receives donations from a number of pharmaceutical and device companies in the diabetes field. A.B. and K.L.C. also report disclosures for Close Concerns, for which several academic institutions, government bodies, and pharmaceutical and device companies in the diabetes field subscribe to the company's fee-based newsletter, Closer Look. B.B. has received research funding from National Institutes of Health, Medtronic, Tandem, Insulet, Xeris, and Dexcom; has served on advisory board or consulted for Novo Nordisk, Tandem, and Convatec; and has received honorarium or expenses from Insulet and Novo Nordisk. T.D. has acted as consultant, advisory board member, or speaker for Abbott, Medtronic, Roche, Lexicon, Menarini, Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Sanofi, Dexcom, and Eli Lilly and has received research grants from Abbott, AstraZeneca, Novo Nordisk, Medtronic, and Sanofi. He is a shareholder of DreaMed Diabetes, Ltd. D.D. has received speaker's honoraria from Dexcom and Insulet. B.F. has served on advisory panels for Eli Lilly, Novo Nordisk and the Kuwait Foundation for Science and has taken part in a speakers' bureau for Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Merck, Sanofi, Roche Diagnostics, and Takeda. R.A.G. is a consultant for Onduo and Health Reveal. G.G. has received research support from Medtronic and Novo Nordisk and is on the speakers' bureau for Eli Lilly, Novo Nordisk, Janssen, Boehringer Ingelheim, Sanofi, and AstraZeneca. I.H. has received a research grant from Medtronic Diabetes and has served as consultant with Abbott Diabetes Care, Adocia, Bigfoot Biomedical, and Roche. P.H., or institutions with which he is associated, received funding from AntriaBio, AstraZeneca, Biocon, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, Roche Diagnostics, and Sanofi for his advisory, research, or speaking activities. L.L.has served as a consultant for Eli Lilly, Sanofi, Novo Nordisk, MannKind, AstraZeneca, Boehringer Ingelheim, Merck, Johnson & Johnson, Dexcom, Insulet, Roche Diagnostics, and Unomedical. C.G.P. has received consulting fees from Animas, CeQur, Dexcom, Insulet, Johnson & Johnson Diabetes Institute, Roche Diabetes Care, Sanofi, and Senseonics. A.L.P. has participated on advisory boards for Abbott Diabetes Care, Becton Dickinson, Bigfoot Biomedical, Boehringer Ingelheim, Eli Lilly, Lexicon, Livongo, Medscape, Merck, Novo Nordisk, Omada Health, Sanofi, and Science 37. She has provided research support for Dexcom and MannKind and is on the speakers' bureau of Novo Nordisk. R.R. is a consultant for Dexcom, Merck, Novo Nordisk, and Intarcia. No other potential conflicts of interest relevant to this article were reported. (diaTribe Foundation, Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Becton Dickinson, Eli Lilly, Merck, Novo Nordisk, Sanofi, Apple Pickers Foundation, Animas, Ascenia, Bigfoot Biomedical, Dexcom, Insulet, Roche, Tandem, Glooko, Helmsley Charitable Trust, Hygieia, Johnson Johnson, Medtronic, National Institutes of Health, Xeris, Abbott, Medtronic Diabetes, AntriaBio, Biocon, GlaxoSmithKline, Janssen, Roche Diagnostics, CeQur, Johnson & Johnson Diabetes Institute, Roche Diabetes Care, Senseonics)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 8×
“R.B.’s nonprofit employer has received consultant payments, research funds, or research supplies on his behalf from Abbott Diabetes Care, Animas, Ascenia, Bigfoot Biomedical, Dexcom, Insulet, Eli Lilly, Roche, and Tandem, with no personal compensation to R.B. R.M.B. declared research support, acted as a consultant, or…”
BackgroundFeig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32400-5 · Cited by 803
Agiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations
Petrie, J. R., Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A., & Heinemann, L. (2017) · Diabetes Care · doi:10.2337/dci17-0043 · Cited by 135
Cited by
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
The relationships between time in range, hyperglycemia metrics, and HbA1c
Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, C., Carlson, A. L., Johnson, M. L., & Rodbard, D. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818822496 · Cited by 479
Positioning time in range in diabetes management
Advani, A. (2020) · Diabetologia · doi:10.1007/s00125-019-05027-0 · Cited by 170
Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline
Galindo, R. J., Umpierrez, G. E., Rushakoff, R. J., Basu, A., Lohnes, S., Nichols, J. H., Spanakis, E. K., Espinoza, J., Palermo, N. E., Awadjie, D. G., et al. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820954163 · Cited by 170
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
Metadata
- Authors
- Beyond A1C Writing Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-05-11
- Volume
- 41
- Issue
- 6
- Pages
- e92-e94
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2994415178
- Cited by
- 86
- References
- 4
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics. https://app.cochat.ai/papers/10.2337/dci18-0010
- The paper
- Beyond A1C Writing Group. (2018). Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics. Diabetes Care. https://doi.org/10.2337/dci18-0010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.